Rare diseases
Investigational molecules
Locations
3611 Valley Centre Drive Suite 300, 92130-3331, United States
Travere Therapeutics Inc. supports research in proteinuric glomerular diseases, with emphasis on focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), IgA nephropathy (IgAN), IgA vasculitis (IgAV), and Alport syndrome. Its studies focus on renal protection, reduction of proteinuria, and preservation of kidney function.
Research activity in this area reflects a strong therapeutic interest in chronic glomerular disease and related kidney injury.
Travere Therapeutics Inc. runs clinical trials in conditions such as Homocystinuria, IgA nephropathy, Focal segmental glomerulosclerosis, Glomerulonephritis minimal lesion, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Belgium
Germany
FranceBelgiumBelgiumIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
